Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in three major investor conferences in September 2025.

The company will attend the Wells Fargo Healthcare Conference (09/05), the Morgan Stanley Global Healthcare Conference (09/08), and the H.C. Wainwright Global Investment Conference (09/09). CEO Mark Erlander will present a fireside chat at the H.C. Wainwright conference at 10:30 AM ET, which will be available via webcast on the company's website.

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025.

Details of the events can be found below.

Wells Fargo 20^th Annual Healthcare Conference
Format: 1x1 Meetings
Date: 09/05/2025
Location: Encore Boston Harbor, Everett, MA

Morgan Stanley 23^rd Annual Global Healthcare Conference
Format: 1x1 Meetings
Date: 09/08/2025
Location: Sheraton New York Times Square, New York, NY

H.C. Wainwright 27^th Annual Global Investment Conference
Format: Fireside Chat and 1x1 Meetings
Presenter: Mark Erlander, CEO
Date: 09/09/2025
Time: 10:30 AM ET
Location: Lotte New York Palace Hotel, New York, NY

Interested parties can register for and access the live webcast for the H.C. Wainwright conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Meghan Bianco
Taft Communications, a division of RF|Binder
609-544-5446
meghan.bianco@rfbinder.com

FAQ

When is Cardiff Oncology (CRDF) presenting at the H.C. Wainwright conference?

Cardiff Oncology's CEO Mark Erlander will present a fireside chat on September 9, 2025, at 10:30 AM ET at the Lotte New York Palace Hotel.

Which investor conferences is Cardiff Oncology (CRDF) attending in September 2025?

Cardiff Oncology is attending three conferences: the Wells Fargo Healthcare Conference (09/05), Morgan Stanley Global Healthcare Conference (09/08), and H.C. Wainwright Global Investment Conference (09/09).

How can investors access Cardiff Oncology's (CRDF) H.C. Wainwright conference presentation?

Investors can access the live webcast by visiting the 'Events' section of Cardiff Oncology's website. A replay will be available after the presentation.

What is Cardiff Oncology's (CRDF) main focus as a company?

Cardiff Oncology is a clinical-stage biotechnology company that leverages PLK1 inhibition to develop novel therapies across a range of cancers.